{
    "clinical_study": {
        "@rank": "95708", 
        "acronym": "STOP-DKD", 
        "arm_group": [
            {
                "arm_group_label": "Pharmacist Telehealth Intervention", 
                "arm_group_type": "Experimental", 
                "description": "Will receive a tailored multi-factorial clinical pharmacist-administered telehealth intervention, which includes medication management and behavioral-educational components. The intervention will occur monthly over 3 years."
            }, 
            {
                "arm_group_label": "Education Control", 
                "arm_group_type": "No Intervention", 
                "description": "Will receive educational material about management of kidney disease"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to help diabetic patients with uncontrolled hypertension (HTN)\n      better understand their risk for Diabetic Kidney Disease (DKD) and to give them specific\n      feedback via a telephone intervention on how to reduce that risk through behavioral changes.\n\n      We hypothesize that patients with DKD and uncontrolled HTN who receive this intervention\n      will have less progression, or a smaller decrease in kidney function, after 3 years when\n      compared to the education control group."
        }, 
        "brief_title": "Simultaneous Risk Factor Control Using Telehealth to slOw Progression of Diabetic Kidney Disease (STOP-DKD)", 
        "completion_date": {
            "#text": "May 2018", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Diabetes", 
            "Hypertension", 
            "Diabetic Kidney Disease"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetic Nephropathies", 
                "Hypertension", 
                "Kidney Diseases"
            ]
        }, 
        "detailed_description": {
            "textblock": "A randomized, controlled trial to slow DKD progression:\n\n        1. Using an innovative telehealth approach that is potentially scalable with  demonstrable\n           efficacy in reducing antecedents of kidney disease, including poor blood pressure,\n           glucose, and lipid control\n\n        2. Enrolling demographically diverse patients from local primary care clinics to allow\n           applicability of our results to the general US population within existing delivery\n           systems; and\n\n        3. Targeting patients with moderate DKD (estimated glomerular filtration rate between\n           45-90 ml/min/1.73m2 with evidence of diabetic nephropathy) and uncontrolled HTN (blood\n           pressure \u2265140/90 mm Hg), accounting for about 20% of all patients with diabetes who\n           disproportionately suffer from end-stage renal disease (ESRD), cardiovascular events,\n           and death."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  age \u226518 and less than75 years\n\n          -  regular use of the Duke University Health System (\u22652 primary care visits in 3 prior\n             yrs)\n\n          -  diagnosis of type 2 diabetes\n\n          -  have at least 2 serum creatinine values available in the 3 prior years, separated by\n             at least 3 months;\n\n          -  preserved kidney function (eGFR between 45-90 ml/min/1.73m2 on most recent\n             creatinine)\n\n          -  evidence of diabetic nephropathy\n\n          -  uncontrolled HTN (1y mean clinic SBP\u2265140 and/or DBP\u226590).\n\n        Exclusion Criteria:\n\n          -  no access to telephone\n\n          -  not proficient in English\n\n          -  nursing home/long-term care facility resident or receiving home health care\n\n          -  impaired hearing/ speech/ vision\n\n          -  participating in another trial (pharmaceutical or behavioral)\n\n          -  planning to leave the area in the next 3 years\n\n          -  pancreatic insufficiency or diabetes secondary to pancreatitis\n\n          -  alcohol abuse (>14 alcoholic beverages/ wk)\n\n          -  diagnosis of non-diabetic kidney disease\n\n          -  active malignancy (other than non-melanomatous skin cancer)\n\n          -  life-threatening disease with death probable within 4 years"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01829256", 
            "org_study_id": "Pro00044811"
        }, 
        "intervention": {
            "arm_group_label": "Pharmacist Telehealth Intervention", 
            "description": "A tailored intervention with medication management and behavioral components. The behavioral modules may include, diet, exercise, weight, tobacco use, medication management, side effects, diabetes education, diabetic kidney disease risk and knowledge and cardiovascular disease (CVD)  /hypercholesterolemia/hypertension risk knowledge.  In addition, individuals will receive individualized information on their 10-year risk for stroke and CVD. Individuals will also receive information on how changing a particular value such as BP or cholesterol levels can reduce subsequent risks. Based on the patient's responses to a series of questions, there will be a provision of tailored feedback to reinforce evidence-based behavior for disease and lifestyle management.", 
            "intervention_name": "Pharmacist  telehealth intervention", 
            "intervention_type": "Behavioral"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 27, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Durham", 
                    "country": "United States", 
                    "state": "North Carolina", 
                    "zip": "27705"
                }, 
                "name": "Duke University Health System Clinics"
            }, 
            "investigator": {
                "last_name": "Hayden B Bosworth, PhD", 
                "role": "Sub-Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Multi-Factorial Intervention to Slow Progression of Diabetic Kidney Disease", 
        "overall_contact": {
            "email": "megan.mcphail@dm.duke.edu", 
            "last_name": "Megan McPhail", 
            "phone": "919-668-0966"
        }, 
        "overall_contact_backup": {
            "email": "felicia.mccant@dm.duke.edu", 
            "last_name": "Felicia McCant", 
            "phone": "919-286-0411"
        }, 
        "overall_official": {
            "affiliation": "Duke University", 
            "last_name": "Uptal Patel, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change in kidney function as measured by estimated glomerular filtration rate based on cystatin C(eGFRcys)", 
            "safety_issue": "No", 
            "time_frame": "Measured at Baseline and again at 36 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01829256"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Change in blood pressure, glucose/HbA1c and urine albumin", 
            "safety_issue": "No", 
            "time_frame": "Measured at baseline and again at 36 months"
        }, 
        "source": "Duke University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Duke University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}